Zobrazeno 1 - 10 of 622 pro vyhledávání: '"LCAR-B38M"'
1
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
2
Akademický článek
Long-term remission and survival in patients with relapsed or refractory multiple myeloma after treatment with LCAR-B38M CAR T cells: 5-year follow-up of the LEGEND-2 trial
Autor: Jie Xu, Bai-Yan Wang, Shan-He Yu, Shi-Jun Chen, Shuang-Shuang Yang, Rui Liu, Li-Juan Chen, Jian Hou, Zhu Chen, Wan-Hong Zhao, Ai-Li He, Jian-Qing Mi, Sai-Juan Chen
Publikováno v: Journal of Hematology & Oncology, Vol 17, Iss 1, Pp 1-13 (2024)
Abstract Background The autologous anti–B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T-cell therapy LCAR-B38M has been approved for the treatment of relapsed and refractory multiple myeloma in many countries across the world und
Externí odkaz: https://doaj.org/article/bd5fe093d29e44bdad66104c6ea27c5c
Zobrazit plný text záznamu
3
Akademický článek
Five-year remission without disease progression in a patient with relapsed/refractory multiple myeloma with extramedullary disease treated with LCAR-B38M chimeric antigen receptor T cells in the LEGEND-2 study: a case report.
Autor: Wang, Bai-Yan1 (AUTHOR), Zhao, Wan-Hong1 (AUTHOR), Chen, Yin-Xia1 (AUTHOR), Cao, Xing-Mei1 (AUTHOR), Yang, Yun1 (AUTHOR), Zhang, Yi-Lin1 (AUTHOR), Wang, Fang-Xia2 (AUTHOR), Zhang, Peng-Yu1 (AUTHOR), Lei, Bo1 (AUTHOR), Gu, Liu-Fang1 (AUTHOR), Wang, Jian-Li1 (AUTHOR), Bai, Ju1 (AUTHOR), Xu, Yan1 (AUTHOR), Wang, Xu-Geng1 (AUTHOR), Zhang, Rui-Li1 (AUTHOR), Wei, Li-Li1 (AUTHOR), Zhuang, Qiu-Chuan3 (AUTHOR), Fan, Frank3 (AUTHOR), Zhang, Wang-Gang1 (AUTHOR), He, Ai-Li4 (AUTHOR)
Publikováno v: Journal of Medical Case Reports. 12/11/2022, Vol. 16 Issue 1, p1-8. 8p.
Zobrazit plný text záznamu
4
Akademický článek
Four-year follow-up of LCAR-B38M in relapsed or refractory multiple myeloma: a phase 1, single-arm, open-label, multicenter study in China (LEGEND-2).
Autor: Zhao, Wan-Hong1 (AUTHOR), Wang, Bai-Yan1 (AUTHOR), Chen, Li-Juan2 (AUTHOR), Fu, Wei-Jun3,4 (AUTHOR), Xu, Jie5 (AUTHOR), Liu, Jie1 (AUTHOR), Jin, Shi-Wei5 (AUTHOR), Chen, Yin-Xia1 (AUTHOR), Cao, Xing-Mei1 (AUTHOR), Yang, Yun1 (AUTHOR), Zhang, Yi-Lin1 (AUTHOR), Wang, Fang-Xia1 (AUTHOR), Zhang, Peng-Yu1 (AUTHOR), Lei, Bo1 (AUTHOR), Gu, Liu-Fang1 (AUTHOR), Wang, Jian-Li1 (AUTHOR), Zhang, Hui1 (AUTHOR), Bai, Ju1 (AUTHOR), Xu, Yan1 (AUTHOR), Zhu, Han2 (AUTHOR)
Publikováno v: Journal of Hematology & Oncology. 7/6/2022, Vol. 15 Issue 1, p1-12. 12p.
Zobrazit plný text záznamu
5
Akademický článek
Five-year remission without disease progression in a patient with relapsed/refractory multiple myeloma with extramedullary disease treated with LCAR-B38M chimeric antigen receptor T cells in the LEGEND-2 study: a case report
Autor: Bai-Yan Wang, Wan-Hong Zhao, Yin-Xia Chen, Xing-Mei Cao, Yun Yang, Yi-Lin Zhang, Fang-Xia Wang, Peng-Yu Zhang, Bo Lei, Liu-Fang Gu, Jian-Li Wang, Ju Bai, Yan Xu, Xu-Geng Wang, Rui-Li Zhang, Li-Li Wei, Qiu-Chuan Zhuang, Frank Fan, Wang-Gang Zhang, Ai-Li He, Jie Liu
Publikováno v: Journal of Medical Case Reports, Vol 16, Iss 1, Pp 1-8 (2022)
Abstract Background Multiple myeloma remains incurable despite treatment advancements over the last 20 years. LCAR-B38M Cells in Treating Relapsed/Refractory Multiple Myeloma was a phase 1, first-in-human, investigator-initiated study in relapsed/ref
Externí odkaz: https://doaj.org/article/c9b293fef2f645698bfc3549329d7fc0
Zobrazit plný text záznamu
7
Akademický článek
Four-year follow-up of LCAR-B38M in relapsed or refractory multiple myeloma: a phase 1, single-arm, open-label, multicenter study in China (LEGEND-2)
Autor: Wan-Hong Zhao, Bai-Yan Wang, Li-Juan Chen, Wei-Jun Fu, Jie Xu, Jie Liu, Shi-Wei Jin, Yin-Xia Chen, Xing-Mei Cao, Yun Yang, Yi-Lin Zhang, Fang-Xia Wang, Peng-Yu Zhang, Bo Lei, Liu-Fang Gu, Jian-Li Wang, Hui Zhang, Ju Bai, Yan Xu, Han Zhu, Juan Du, Hua Jiang, Xiao-Hu Fan, Jian-Yong Li, Jian Hou, Zhu Chen, Wang-Gang Zhang, Jian-Qing Mi, Sai-Juan Chen, Ai-Li He
Publikováno v: Journal of Hematology & Oncology, Vol 15, Iss 1, Pp 1-12 (2022)
Abstract Background LCAR-B38M is a chimeric antigen receptor T cell product with two binding domains targeting B cell maturation antigen. Our previous reports showed a remarkable efficacy of LCAR-B38M in patients with relapsed/refractory multiple mye
Externí odkaz: https://doaj.org/article/680bd4fe1f994d6db669554110364f34
Zobrazit plný text záznamu
8
Akademický článek
A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma
Autor: Wan-Hong Zhao, Jie Liu, Bai-Yan Wang, Yin-Xia Chen, Xing-Mei Cao, Yun Yang, Yi-Lin Zhang, Fang-Xia Wang, Peng-Yu Zhang, Bo Lei, Liu-Fang Gu, Jian-Li Wang, Nan Yang, Ru Zhang, Hui Zhang, Ying Shen, Ju Bai, Yan Xu, Xu-Geng Wang, Rui-Li Zhang, Li-Li Wei, Zong-Fang Li, Zhen-Zhen Li, Yan Geng, Qian He, Qiu-Chuan Zhuang, Xiao-Hu Fan, Ai-Li He, Wang-Gang Zhang
Publikováno v: Journal of Hematology & Oncology, Vol 11, Iss 1, Pp 1-8 (2018)
Abstract Background Chimeric antigen receptor (CAR) T cell therapy has demonstrated proven efficacy in some hematologic cancers. We evaluated the safety and efficacy of LCAR-B38M, a dual epitope-binding CAR T cell therapy directed against 2 distinct
Externí odkaz: https://doaj.org/article/465fd456636849ce93bd874e19984b0a
Zobrazit plný text záznamu
9
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
10
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje